Orchestra BioMed (NASDAQ: OBIO) set for up to $21M proceeds

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. reported that it expects to receive up to $21 million in proceeds in connection with the acquisition of Vivasure by Haemonetics. The company disclosed this development via a press release titled “Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics,” which is filed as an exhibit to this report.

Insights

Healthcare & Capital Markets Analyst

Orchestra BioMed highlights potential proceeds of up to $21 million tied to a third-party acquisition.

Orchestra BioMed states it may receive up to $21 million in proceeds resulting from the acquisition of Vivasure by Haemonetics. The report itself does not describe the underlying contractual terms, timing, or conditions for these proceeds, only that this information appears in an attached press release.

From an investor perspective, a potential cash inflow of this size can matter for a clinical-stage or growth-focused healthcare company, depending on its existing cash position and burn rate, which are not detailed here. The actual impact will depend on whether the full amount is realized and any milestones or contingencies described in the referenced press release.

false 0001814114 0001814114 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

ORCHESTRA BIOMED HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-39421 (Commission File Number)	92-2038755 (IRS Employer Identification No.)
150 Union Square Drive New Hope, Pennsylvania 18938 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (215) 862-5797 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	OBIO	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On January 12, 2026, Orchestra BioMed Holdings, Inc. (the “Company”) issued a press release titled “Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics,” which press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release, dated January 12, 2026.

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ORCHESTRA BIOMED HOLDINGS, INC.
	By:	/s/ Andrew Taylor
	Name:	Andrew Taylor
	Title:	Chief Financial Officer
Date: January 12, 2026

3

FAQ

What did Orchestra BioMed (OBIO) report in this 8-K filing?

Orchestra BioMed reported that it expects to receive up to $21 million in proceeds related to the acquisition of Vivasure by Haemonetics, as described in an attached press release.

How much money could Orchestra BioMed (OBIO) receive from the Vivasure acquisition?

The company indicates it could receive up to $21 million in proceeds in connection with the acquisition of Vivasure by Haemonetics.

Where can investors find more details about Orchestra BioMed’s expected $21 million in proceeds?

Details are provided in the press release titled “Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics”, attached as Exhibit 99.1.

Does the filing explain the terms or timing of the up to $21 million in proceeds for Orchestra BioMed?

The filing notes only that Orchestra BioMed expects to receive up to $21 million in proceeds and refers readers to the attached press release for further information.

Which companies are involved in the transaction linked to Orchestra BioMed’s potential proceeds?

The potential proceeds to Orchestra BioMed are connected to the acquisition of Vivasure by Haemonetics, as described in the company’s press release.